Yahoo
NYSE - Delayed Quote USD

CONMED Corporation (CNMD)

49.32 -0.10 (-0.20%)
At close: September 4 at 4:00:03 PM EDT
49.50 +0.18 (+0.36%)
After hours: September 4 at 7:56:04 PM EDT
Trade CONMED on Coinbase
Chart Range Bar
Loading chart for CNMD
  • Previous Close 49.42
  • Open 49.09
  • Bid 49.27 x 30000
  • Ask 49.41 x 70000
  • Day's Range 48.61 - 49.51
  • 52 Week Range 31.44 - 54.81
  • Volume 281,280
  • Avg. Volume 584,383
  • Market Cap (intraday) 1.477B
  • Beta (5Y Monthly) 0.91
  • PE Ratio (TTM) 26.80
  • EPS (TTM) 1.84
  • Earnings Date (est.) Nov 4, 2026
  • Forward Dividend & Yield 0.80 (1.62%)
  • Ex-Dividend Date Sep 15, 2025
  • 1y Target Est 45.50

CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as supporting products include powered resection instruments , fluid management, and visualization systems and the related single-use products that enable surgeons to perform minimally invasive sports medicine surgeries. It also provides battery-powered, autoclavable, large, and small bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under the Hall surgical brand name. In addition, the company offers general surgery products, such as clinical insufflation systems under the AirSeal brand; smoke removal devices under the Buffalo Filter brand; endomechanical products, including the Anchor1 line of tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors, used in minimally invasive surgeries; and electrosurgical solution comprise monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems, and other accessories. Further, it provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products to treat diseases of dilation, hemostasis, biliary, stricture management, infection prevention, and patient monitoring include ECG electrodes, EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. The company was incorporated in 1970 and is headquartered in Largo, Florida.

www.conmed.com

3,900

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CNMD
21.48%
S&P 500 (^GSPC)
12.75%

1-Year Return

CNMD
9.48%
S&P 500 (^GSPC)
18.71%

3-Year Return

CNMD
54.23%
S&P 500 (^GSPC)
70.93%

5-Year Return

CNMD
60.36%
S&P 500 (^GSPC)
70.18%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 343.49M
Earnings 23.07M
Profit Margin 6.72%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
100M
200M
300M
2.0%
4.0%
6.0%

Analyst Insights

View More

Analyst Price Targets

43.00 Low
45.50 Average
49.32 Current
49.00

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 7/30/2026
Analyst Piper Sandler
Rating Action Reiterates
Rating Neutral
Price Action Raises
Price Target 39 -> 45

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (5yr expected)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    4.12%

  • Return on Assets (ttm)

    4.14%

  • Return on Equity (ttm)

    5.53%

  • Revenue (ttm)

    1.37B

  • Net Income Avi to Common (ttm)

    56.5M

  • Diluted EPS (ttm)

    1.84

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    37.33M

  • Total Debt/Equity (mrq)

    80.11%

  • Levered Free Cash Flow (ttm)

    131.36M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: